ASCE+ HRLV Exosomes are produced using controlled biotechnology processes that ensure purity, consistency, and stability. Unlike lower grade or unstandardized exosome solutions, this formulation maximizes regenerative signaling. The high concentration of extracellular vesicles allows for more efficient communication with follicle cells compared to diluted or poorly characterized alternatives.

HRLV contains several peptides, including Copper Tripeptide-1 (GHK-cu) and growth-factor peptides, as part of its advanced scalp-care formulation.

Each vial contains 10 billion bioactive extracellular vesicles, delivering an exceptionally high signaling load to the scalp. This density is what allows exosomes to stand apart from traditional growth factor treatments like PRP & PRF.

Exosome Therapy is most effective when performed as a series. Treatment frequency and total sessions depend on the individual. Packages are designed to support cumulative results over time rather than single session outcomes.

Results are not immediate. While some clients notice improvements in scalp quality earlier, visible changes in hair should be expected no sooner than four months after completing the full recommended series of sessions. This timeframe aligns with the natural hair growth cycle, as follicles require time to respond, transition into growth phases, and produce measurable changes in hair.

Exosome Therapy is not suitable during pregnancy, active scalp infections, uncontrolled autoimmune conditions, or certain medical circumstances. Suitability is assessed prior to treatment.